Research Interests
anthropology/ethnography
,
cancer/oncogenesis
,
information sciences
,
transgenics
Recent Publications
Aklilu M, Hussain A, Evans CP, Hannon RA, Lipton A, Dimairo M, Yu J, Zobel P, Torti FM, Finkelman RD.
A phase II, randomized, open-label, pilot study to evaluate the safety and the effects on bone resorption of saracatinib (AZD0530) in patients with prostate cancer or breast cancer with metastatic bone disease [abstract]. Bone.
2011;
48(1):S17.
Stacey RB, Kock ND, D'Agostino RB Jr, Torti FM, Eckman DM, Sane DC, Workman S, Lane KS, Hundley WG.
Doxorubicin associated changes in coronary artery histology [abstract]. J Am Coll Cardiol.
2011;
57(14 Suppl 1):E1591.
Ding X, Singh R, Burke A, Hatcher H, Olson J, Kraft RA, Schmid M, Carroll D, Bourland JD, Akman S, Torti FM, Torti SV.
Development of iron-containing multiwalled carbon nanotubes for MR-guided laser-induced thermotherapy. Nanomedicine (Lond).
2011;
6(8):1341-1352.
Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG.
Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol.
2010;
28(1):166-172.
Li L, Fang CJ, Ryan JC, Niemi EC, Lebron JA, Bjorkman PJ, Arase H, Torti FM, Torti SV, Nakamura MC, et al.
Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A.
2010;
107(8):3505-3510.
Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM.
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med.
2010;
2(43):43ra56.
Twomley K, D'Agostino R Jr, Lawrence J, Melin S, Ellis LR, Stacey B, Hamilton CA, Torti F, Little W, Hundley W.
Early and persistent evidence of subclinical cardiovascular injury after receipt of anthracycline chemotherapy [abstract]. Circulation.
2010;
122(21 Suppl):A12766.
Jiao Y, Wilkinson J IV, Di X, Wang W, Hatcher H, Kock ND, D'Agostino R Jr, Knovich MA, Torti FM, Torti SV.
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood.
2009;
113(2):462-469.
Xu J, Kibel AS, Turner AR, Pruett K, Zheng SL, Sun J, Kim S-T, Hsu F-C, Torti FM, Chang B-L, et al.
Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev.
2009;
18(7):2145-2149.
Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG.
Subclinical cardiovascular toxicity of anthracyclines identified with cardiovascular magnetic resonance imaging [abstract]. Circulation.
2009;
120(18 Suppl):S299.
Laubenbacher R, Hower V, Jarrah A, Torti SV, Shulaev V, Mendes P, Torti FM, Akman S.
A systems biology view of cancer. Biochim Biophys Acta.
2009;
1796(2):129-139.
Storey JA, Connor RF, Lewis ZT, Hurd D, Pomper G, Keung YK, Lovato J, Torti SV, Torti FM, Molnar I, et al.
The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol.
2009;
2():article 44.
Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.
Phase I study of angiotensin-(1-7), an endogenous antiangiogenic hormone: clinical, pharmacokinetic, and biomarker findings [abstract]. Mol Cancer Ther.
2009;
8(12 Suppl 1):B208.
Burke A, Singh R, Kraft RA, Levi-Polyachenko N, Hatcher HC, D'Agostino R Jr, Kock ND, Carroll DL, Akman S, Torti FM, Torti SV, et al.
Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A.
2009;
106(31):12897-902.
Blish KR, Wang W, Willingham MC, Du W, Brown JC, Hawkins GA, Garvin AJ, D'Agostino RB Jr, Torti FM, Torti SV, et al.
A human bone morphogenetic protein antagonist is down-regulated in renal cancer. Mol Biol Cell.
2008;
19(2):457-464.
Coffman LG, Brown JC, Johnson DA, Parthasarathy N, D'Agostino RB Jr, Lively MO, Hua X, Willingham MC, Torti FM, Torti SV, et al.
Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol.
2008;
294(3):L505-L515.
Ryan CJ, Small EJ, Torti FM.
Testicular cancer. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloff's clinical oncology. 4th ed.
Philadelphia: Churchill Livingstone/Elsevier;
2008:
1713-1744.
Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.
Bi-directional translational research with angiotensin-(1-7) uncovers placental growth factor as a therapeutic target [abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research ; 2008 Apr 12-16; San Diego (CA). Philadelphia (PA): AACR.
2008;
():Abstr 4968.
Petty WJ, Miller AA, McCoy TP, Gallagher PE, Tallant EA, Torti FM.
Phase I trial of angiotensin-(1-7): an endogenous anti-angiogenic hormone [abstract]. J Clin Oncol.
2008;
26(15 Suppl):634s.
Huber WW, Haslinger E, Schachner D, Parzefall W, Grasl-Kraupp B, Hochreiter A, Lang H, Torti SV, Torti FM, Schulte-Hermann R.
The carcinogen azonymethane causes necrosis and oxidative stress in rat liver within 48 hours after injection, a toxic effect that is however strongly mitigated by pretreatment with the coffee components kahweol and cafestol [abstract]. Naunyn Schmiedebergs Arch Pharmacol.
2007;
375(Suppl 1):94.
Jiao Y, Kennedy DP, Cho JH, Planalp R, Bou-Abdallah F, Chasteen ND, Wilkinson J, Wang W, Torti FM, Torti SV.
Curcumin, a cancer chemopreventive agent, is a biologically relevant iron chelator [abstract]. Am J Hematol.
2007;
82(6):515.
Han J, Seaman WE, Torti FM, Torti SV.
Ferritin-mediated iron transport via TIM-2 in mouse kidney cells [abstract]. Am J Hematol.
2007;
82(6):517.
Li L, Torti SV, Torti FM, Hayashi S, Seaman WE.
Structural requirements for the endocytosis of H-ferritin by murine TIM-2 [abstract]. Am J Hematol.
2007;
82(6):586.
Torti FM, Coffman LG, Brown JC, Torti SV, Parthasarathy N, D'Agostino RB.
Ferritin inhibits cleavage of high molecular weight kininogen by elastase and mast cell tryptase [abstract]. Am J Hematol.
2007;
82(6):508-509.
Torti FM, Wang W, Di X, Torti SV.
Extensive excess capacity of the IRP system in cellular iron regulation [abstract]. Am J Hematol.
2007;
82(6):565.
Torti SV, Byrne F, Whelan O, Levi N, Ucer B, Schmid M, Torti FM, Akman S, Liu J, Ajayan PM, et al.
Thermal ablation therapeutics based on CN(x) multi-walled nanotubes. Int J Nanomedicine.
2007;
2(4):707-714.
Finkelman D, Torti FM, Lipton A, Hannon RA, Hussain A, Evans C, Akilu M, Iacona R, Swaisland A, Stuart M.
A phase II pilot study of safety and effects on bone resorption of AZD0530 in prostate or breast cancer patients with bone metastases [abstract]. J Bone Miner Res.
2007;
22(Suppl 1):S409.
Storey JA, Connor R, Lewis ZT, Lovato J, Hurd D, Torti FM, Molnar I.
The transfusion iron overload score is a potential predictor of survival in stem cell transplant patients [abstract]. Blood.
2007;
110(11 Pt 1):336A.
All Publications
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.